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	 A	novel,	 sensitive	and	convenient	method	 for	 the	determination	of	 tizanidine	hydrochloride
(TZD)	 based	 on	 the	 fluorescence	 quenching	 of	 thioglycolic	 acid‐capped	 CdS	 quantum	 dots
(TGA‐CdS	 QDs)	 is	 proposed.	 Luminescent	 CdS	 semiconductor	 quantum	 dots	 modified	 by
thioglycolic	 acid	 were	 synthesized	 from	 cadmium	 nitrate	 and	 sodium	 sulfide	 in	 alkaline
aqueous	 solution.	 The	 modified	 CdS	 QDs	 are	 water‐soluble,	 stable	 and	 highly	 luminescent.
When	TZD	was	added	into	the	CdS	QDs	colloidal	solution,	the	surface	of	CdS	QDs	generates	the
electrostatic	 interaction	 in	 aqueous	 medium,	 which	 induces	 the	 quenching	 of	 fluorescence
emission	 at	 518	 nm	 upon	 excitation	 at	 340	 nm.	 Under	 the	 optimal	 conditions,	 the	 Stern‐
Volmer	 calibration	plot	 of	Fο/F	against	 concentration	of	 TZD	was	 linear	 in	 the	 range	 of	 3.0‐
18.0	μg/mL	with	a	correlation	coefficient	of	0.9953.	The	detection	limit	was	1.35	μg/mL.	The
relative	standard	deviation	for	five	determinations	of	9	μg/mL	TZD	was	2.29%.	The	proposed
method	was	successfully	applied	to	commercial	 tablets	with	satisfactory	results.	The	results
were	 found	 to	 be	 in	 good	 agreement	 with	 those	 obtained	 by	 the	 reference	 method.	The
possible	fluorescence	quenching	mechanism	for	the	reaction	is	also	discussed.	
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1.	Introduction	
	
Tizanidine	 (TZD),	 5‐chloro‐N‐(4,5‐dihydro‐1H‐imidazol‐2‐
yl)benzo[c][1,2,5]thiadiazol‐4‐amine	 is	 an	 α2‐adrenergic	
agonist	 and	 centrally	 active	 myotonolytic	 skeletal	 muscle	
relaxant	with	 a	 chemical	 structure	 unrelated	 to	 other	muscle	
relaxants	 [1].	 It	 reduces	 spasticity	 by	 increasing	 presynaptic	
inhibition	 of	motor	 neurons.	 It	 also	 reduces	 increased	muscle	
tone	 associated	 with	 spasticity	 in	 patients	 with	 multiple	
sclerosis	 or	 spinal	 cord	 injury.	 Two	 and	 four	 mg	 tablets	 are	
available	for	oral	administration.		
Few	 methods	 have	 been	 described	 for	 the	 determination	 of	
TZD	in	pharmaceutical	preparations	or	biological	fluids.	These	
methods	 include	 spectrophotometry	 [2,3],	 gas	 chromato‐
graphy‐mass	 spectrometry	 [4],	HPTLC	 [1,5]	 and	HPLC	 [1,6‐8].	
Besides,	a	radioimmunoassay	method	for	 the	quantification	of	
TZD	 hydrochloride	 has	 been	 described	 [9].	 It	 is	worth	 noting	
that	 no	 previous	 spectrofluorometric	 method	 has	 been	
reported	for	the	determination	of	TZD.	
The	 fluorescence	 probe	 method	 has	 been	 increasingly	
employed	 due	 to	 its	 simplicity,	 selectivity,	 and	 cost‐effective	
nature	[10,11].	As	a	kind	of	novel	fluorescence	probe,	quantum	
dots	 (QDs)	 have	 always	 been	 used	 in	 biology	 and	 medicine	
recently,	especially	in	analytical	chemistry	[12].	
Compared	 to	 organic	 fluorophores,	 QDs	 exhibit	 higher	
quantum	 yield,	 color	 availability,	 good	 photo‐stability,	 large	
surface‐to‐volume	 ratio	 and	 surface	 functionality	 [10].	 Thus,	
QDs	possess	highly	attractive	fluorescent	properties	to	be	ideal	
fluorescent	indicators	for	chemical	and	biological	assay.	
Direct	 aqueous‐phase	 synthesis	 of	 semiconductor	 nano‐
crystals	 with	 high	 photoluminescence	 quantum	 yield	 would	
provide	a	 convenient,	 economic,	 and	environmentally	 friendly	
alternative	 to	 the	 labor‐intensive	 method	 of	 organic‐phase	
synthesis	 followed	 by	 ligand	 exchange.	 CdS	 nanocrystals	
represent	 one	 material	 that	 can	 be	 both	 fabricated	 and	
functionalized	 in	a	single	synthetic	 step	 [13].	Compatible	with	
aqueous	 assay	 condition,	 the	 surface	 modified	 quantum	 dots	
are	 usually	 capped	 with	 some	 appropriate	 hydrophilic	
functional	 reagents	 used	 as	 stabilizing	 agents,	 such	 as																		
L‐cysteine,	 thioglycollic	 acid	 (TGA)	 and	 so	 on.	 These	 surface	
modification	 reagents	 of	 QDs	 may	 change	 their	 optical	 and	
chemical	properties.	On	one	hand,	these	agents	can	modify	the	
surface	 of	 QDs	 to	 diminish	 the	 QDs’	 crystal	 defect.	 So	 the	
intensity	of	fluorescence	would	be	much	stronger.	On	the	other	
hand,	 QDs	would	 be	 hydrophilic,	 so	 they	 could	 participate	 in	
the	 reaction	 in	 aquatic	 condition.	 The	 interactions	 between	
some	substances	and	the	modified	quantum	dots	would	change	
their	photophysical	and	photochemical	properties	[14].	
Due	 to	 the	 lack	 of	 spectrofluorometric	 methods	 for	 the	
determination	 of	 TZD,	 the	 aim	 of	 the	 present	 work	 was	 to	
develop	 a	 sensitive,	 reproducible	 and	 simple	 spectrofluoro‐
metric	method	for	TZD	determination	in	bulk	or	in	tablets.	TZD	
has	 no	 native	 fluorescence,	 thus,	 it	 was	 deemed	 useful	 to	
investigate	 the	 interaction	 between	 thioglycolic	 acid‐capped	
CdS	quantum	dots	(TGA‐CdS	QDs)	and	TZD.	As	a	result,	 it	was	
found	that	the	fluorescence	intensity	of	CdS	QDs	is	quenched	in	
the	 presence	 of	 TZD	 in	 aqueous	 medium.	 The	 quenched	
intensity	of	fluorescence	was	proportional	to	the	concentration	
of	 TZD.	 Based	 on	 this	 phenomenon,	 a	 new	 method	 for	 the	
determination	 of	 TZD	 by	 this	 fluorescent	 technique	 was	
developed.	The	method	has	been	applied	in	the	determination	
of	TZD	in	commercial	tablets	with	satisfactory	results.	
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2.	Experimental	
	
2.1.	Instrumentation	
	
The	 spectra	 and	 intensity	 of	 fluorescence	were	measured	
with	 a	 RF‐1501	 Shimadzu	 spectrofluorophotometer	 (Japan).	
UV‐vis	 absorption	 spectra	 were	 recorded	 with	 a	 Shimadzu	
Ultraviolet/visible	 recording	 spectrophotometer	 UV‐1600	
(Japan).	 The	 transmission	 electron	microscopic	 (TEM)	 images	
of	 the	 nanoparticles	 were	 obtained	 using	 a	 JEM‐2100	
transmission	electron	microscope	(JEOL,	Japan).	
	
2.2.	Reagents	and	reference	samples	
	
Pharmaceutical	 grade	of	TZD	and	Sirdalud®	 tablets	 (batch	
number	Y0045)	nominally	containing	TZD	(4	mg),	were	kindly	
supplied	 by	Novartis	 Pharma	 Egypt	 (Cairo,	 Egypt).	 Potassium	
dihydrogen	 phosphate	 and	 orthophosphric	 acid	 (85%)	 were	
purchased	 from	 VWR	 Chemicals	 (Pool,	 England).	 Bi‐distilled	
water	was	produced	 in‐house	 (Aquatron	Water	 Still,	 A4000D,	
UK).	 Cadmium	 nitrate,	 sodium	 sulphide	 and	 thioglycolic	 acid	
(extra‐pure,	80%)	were	purchased	from	Loba	Chemie	PVT	LTD	
(India).	 All	 other	 chemicals	 and	 reagents	 used	 were	 of	
analytical	 grade	 unless	 indicated	 otherwise.	 Standard	 stock	
solution	of	TZD	(0.1	mg/mL)	was	prepared	by	dissolving	10	mg	
of	the	drug	in	100	mL	water	in	a	volumetric	flask	and	then	the	
required	concentrations	were	prepared	by	serial	dilutions.	
	
2.3.	Procedure	
	
2.3.1.	Preparation	of	TGA‐capped	CdS	QDs	
	
Functionalized	TGA	capped	CdS	QDs	were	synthesized	via	
the	 procedure	 described	 by	 Winter	 et	 al.	 [13],	 with	 some	
modifications.	 0.3	 mL	 TGA	 were	 added	 to	 10	 mL	 of	 15	 mM	
Cd(NO3)2.	 The	 mixture	 was	 adjusted	 to	 pH	 =	 7.0	 ±	 0.05	 by	
dropwise	 addition	 of	 0.5	 M	 NaOH.	 Ten	 milliliters	 of	 6	 mM	
Na2S.9H2O	 solution	 were	 added	 to	 this	 solution	 with	 rapid	
stirring,	which	raised	the	pH	to	∼8.5.	The	reaction	mixture	was	
stirred	 for	2	h.	The	solution	was	quantitavely	 transferred	 into	
100	mL	volumetric	flask	and	completed	to	volume	with	water.	
The	CdS	QDs	made	according	to	this	procedure	are	about	4	nm.	
	
2.3.2.	Standard	procedure	for	spectrofluorometric	
determination	of	TZD	
	
In	a	10	mL	volumetric	flask,	0.3	mL	of	CdS	QDs	solution	and	
an	 appropriate	 volume	 of	 TZD	 standard	 stock	 solution	 or	
sample	 solution	 were	 transferred.	 After	 10	 minutes,	 the	
mixture	 was	 diluted	 to	 volume	 with	 water	 and	 mixed	
thoroughly.	 The	 fluorescence	 intensity	 of	 the	 solution	 was	
recorded	at	518	nm	with	the	excitation	wavelength	of	340	nm.	
Both	slit	widths	of	excitation	and	emission	were	10	nm.	
	
2.3.4.	Sample	treatment	
	
For	 the	 pharmaceutical	 analysis,	 10	 tablets	were	weighed	
and	powdered	 in	 a	mortar.	 An	 accurately	weighed	 amount	 of	
the	powder	equivalent	to	10	mg	TZD	was	extracted	with	water	
(3x20	 mL)	 and	 filtered	 into	 a	 100	 mL	 volumetric	 flask.	 The	
solution	 was	 completed	 to	 volume	 with	 water	 to	 obtain	 a	
concentration	equivalent	to	0.1	mg/mL	TZD.	
	
3.	Results	and	discussion	
	
3.1.	Characterization	of	TGA	capped	CdS	QDs	
	
The	 water	 soluble,	 TGA	 functionalized,	 CdS	 QDs	 were	
successfully	synthesized	according	to	the	protocol	described	in	
section	 2.	 The	 average	 size	 of	 the	 particle	 is	 about	 4	 nm	 as	
analyzed	by	TEM	(Figure	1).	The	TEM	image	shows	clearly	that	
these	 QDs	 are	 monodisperse.	 The	 optical	 properties	 of	 TGA	
capped	 CdS	QDs	were	 characterized	 by	 UV‐visible	 absorption	
spectrometry	 and	 fluorescence	 spectroscopy,	 which	 are	
powerful	 tools	 to	 confirm	 quantum‐confined	 property	 of	
semiconductor	 QDs,	 as	 shown	 in	 Figure	 2.	 The	 emission	 and	
excitation	wavelengths	 of	 the	particles	were	518	nm	and	340	
nm,	respectively.	
	
 
	
Figure	1. Transmission	electron	microscopy	image	of	water‐soluble	TGA‐CdS	
quantum	dots.	
	
 
	
Figure	2. Excitation	 at	 340	 nm	 (a)	 and	 emission	 at	 518	 nm	 (b)	 spectra	 of	
TGA‐CdS	quantum	dots.	
	
3.2.	Reaction	time	and	stability	
	
Fluorescence	 spectra	 were	 recorded	 at	 different	 time	
intervals	after	the	addition	of	TZD	into	the	QDs	solution,	Figure	
3.	 The	 resulted	 spectra	 showed	 that	 all	 reactions	 were	
completed	within	5	min,	hence,	the	fluorescence	spectrum	was	
recorded	at	10	min	after	the	addition	of	TZD.	The	fluorescence	
signals	 of	 the	 adduct	 were	 stable	 for	 more	 than	 180	 min.	
Therefore,	 this	 system	 exhibits	 rapid	 reaction	 and	 good	
stability.	 It	 is	worth	noting	that	the	prepared	TGA	capped	CdS	
QDs	were	found	to	be	stable	for	at	least	two	months.	
	
	
	
Figure	3.	Effect	of	reaction	time	1	mL	TGA‐CdS	QDs;	9	µg/mL	tizanidine.	
	
3.3.	Effect	of	pH	
	
The	effect	of	pH	in	a	range	between	3.0	and	6.0	was	studied	
in	 order	 to	 select	 the	 optimum	 conditions	 for	 the	
determination.	Phosphate	buffer	solution	(20	mM)	was	used	to	
adjust	the	acidity	of	the	aqueous	medium.	The	results	showed	
that	pH	 influences	 the	 fluorescence	 intensity	 of	both	QDs	 and	
QDs	 after	 adding	 TZD.	 The	 maximum	 value	 of	 relative	
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fluorescence	 intensity	 (Fο/F)	 was	 obtained	 in	 the	 pH	 of	 5.0.	
However,	 optimum	 linearity	 with	 the	 highest	 correlation	
coefficient	 was	 obtained	 when	 the	 study	 was	 conducted	
without	the	addition	of	phosphate	buffer.	
	
3.4.	Mechanism	of	the	interaction	of	TGA‐CdS	QDs	with	
tizanidine	
	
Quenching	of	FL	emission	 from	QDs	may	occur	by	several	
mechanisms:	 energy	 transferring,	 charge	 diverting,	 surface	
absorption,	 and	 surface	 bound	 complexation	 equilibrium	
attraction	[10].	To	explore	the	reason	of	fluorescence	intensity	
decrease,	 the	UV‐vis	absorption	spectra	of	TGA‐CdS	QDs	were	
investigated	in	the	absence	and	presence	of	TZD,	Figure	4.	The	
results	showed	that	TZD	had	no	absorption	in	the	330	‐	460	nm	
wavelength	range.	Thus,	we	can	get	that	the	quenching	effect	of	
the	fluorescence	of	TGA‐CdS	QDs	added	TZD	was	not	attributed	
to	 the	 absorption	 of	 the	 emission	 wavelength	 by	 TZD.	 From	
Figure	 5,	 we	 can	 observe	 a	 blue‐shift	 with	 increase	 in	
concentration	of	TZD	on	the	emission	spectra	maximum.	Thus,	
we	believe	that	the	TZD	binding	to	the	TGA‐CdS	QDs	made	the	
surface	of	the	particles	change,	which	induce	the	quench	of	QDs	
fluorescence.	 Besides,	 no	major	 change	was	 observed	 for	 the	
TGA‐CdS	QDs	absorption	spectra	before	and	after	adding	TZD,	
which	 also	means	 TGA‐CdS	 QDs	 do	 not	 aggregate	 or	 become	
smaller	after	adding	TZD	[15].	
	
	
	
Figure	4.	Absorption	spectra	of	TGA‐CdS	QDs	(a),	CdS	QDs	adding	tizanidine	
(b)	and	tizanidine	(c).	
	
	
	
	
Figure	 5.	 Effect	 of	 tizanidine	 on	 the	 emission	 of	 TGA‐CdS	 QDs.	 The	
concentrations	of	tizanidine	were	(a)	0	µg/mL,	(b)	3	µg/mL,	(c)	6	µg/mL,	(d)	
9	µg/mL,	(e)	12	µg/mL,	(f)	15	µg/mL,	and	(g)	18	µg/mL.	
	
3.5.	Calibration,	precision	and	accuracy	
	
The	 fluorescence	 spectra	 of	 TGA‐CdS	 QDs	with	 TZD	were	
recorded	 at	 optimum	 experimental	 conditions.	 The	
fluorescence	 intensity	 of	 TGA‐CdS	 QDs	 was	 significantly	
decreased	with	the	addition	of	TZD	(Figure	5).	Considering	this	
significant	 quenching	 of	 fluorescence	 intensity,	 the	 possibility	
of	 developing	 this	 into	 a	 sensitive	 method	 for	 TZD	 was	
evaluated.	It	was	found	that	TZD	quenched	the	fluorescence	of	
QDs	 in	 concentration‐dependent	 manner	 that	 were	 best	
described	by	 the	Stern‐Volmer	 relationship,	which	 is	given	by	
Equation	1.	
	
F0/F	=	1	+	KSV[C]	 	 	 	 	 (1)	
	
F0	and	F	are	 the	 fluorescence	 intensity	of	 the	TGA‐CdS	QDs	at	
em	 when	 excited	 at	 ex	 in	 the	 absence	 and	 presence	 of	 TZD,	
respectively.	 [C]	 is	 the	 concentration	 of	 TZD,	 and	 KSV	 is	 the	
Stern‐Volmer	 quenching	 constant,	 which	 was	 found	 to	 be	
0.0582.	 Under	 optimal	 conditions,	 the	 relative	 fluorescence	
intensities	 of	 TGA‐CdS	 QDs	 were	 decreased	 linearly	 with	
increasing	 TZD	 in	 the	 range	 of	 3.0	 to	 18.0	 μg/mL	 (Figure	 6).	
The	 linear	 regression	 equation	 is	 F0/F=0.0635	 x	 C	 +	 0.9724.	
The	correlation	coefficient	(r2)	is	0.9953.	The	limit	of	detection	
(S/N	=	3)	was	1.35	µg/mL.	
	
	
	
Figure	6.	Stern‐Volmer	plot	of	tizanidine	concentration	dependence	of	the	FL	
intensity	of	QDs	with	a	0.9958	correlation	coefficient.	
	
To	assess	the	precision	of	the	method,	determinations	were	
carried	out	for	a	set	of	5	measurements	of	9	µg/mL	TZD	under	
optimal	 conditions.	 The	 %R.S.D.	 for	 five	 determinations	 was	
2.29%.	
Accuracy	of	 the	results	was	calculated	by	%	recovery	of	6	
different	 concentrations	 of	 TZD	 other	 than	 those	 of	 the	
calibration	curve	and	done	by	another	analyst	and	on	another	
instrument	 of	 the	 same	 type	 to	 test	 the	 reproducibility	 of	 the	
method	as	well.	The	results	obtained	including	the	mean	of	the	
recovery	and	standard	deviation	are	displayed	in	Table	1.	
	
Table	1.	Statistical	comparison	between	the	results	of	the	proposed	method	
and	the	reference	method	for	the	determination	of	tizanidine	hydrochloride	
Statistical		
Term
Reference		
Methoda,b
Spectrofluorometric		
Method	
Mean 100.12 100.47	
S.D.± 1.34 1.33	
S.E.	± 0.55 0.54	
%R.S.D. 1.34 1.32	
N	 6	 6	
V 1.80 1.77	
t	(*2.306) 0.45	 	
F	(*6.39)	 1.02	 	
a	Figures	in	parentheses	are	the	theoretical	t	and	F	values	at	(p	=	0.05).	
b	Company's	method	(Spectrophotometric	method	at	λmax	320	nm	in	water).	
	
3.6.	Tolerance	of	foreign	substance	
	
The	 tablets	 often	 contained	 the	 following	 excipients:	
microcrystalline	cellulose,	 lactose,	silicon	dioxide	colloidal	and	
stearic	 acid;	while	 in	 capsules,	 the	main	diluent	 is	 sucrose.	 In	
order	 to	 assess	 the	 selectivity	 of	 the	 proposed	 method,	 the	
tolerance	 of	 levels	 of	 coexisting	 excipients	 was	 tested	 by	
preparing	solutions	of	TZD	and	different	concentration	of	each	
excipient.	The	solution	was	mixed	thoroughly	and	was	added	to	
TGA‐CdS	QDs	 solution.	Most	 of	 the	 excipients	 are	 tolerated	 at	
relatively	 low	 levels	 (±3%).	 Accordingly,	 the	 excipients	 have	
hardly	 any	 effect	 on	 fluorescence	of	 CdS	QDs	 and	 the	method	
has	a	high	selectivity.	So	the	method	is	practical	and	valuable.	
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3.7.	Application	
	
The	 present	 method	 was	 applied	 to	 determine	 TZD	 in	
Sirdalud®	tablets.	Results	are	given	in	Table	2.	The	%R.S.D.	was	
2.12%,	and	the	results	obtained	by	the	present	method	agreed	
with	the	labeled	values	for	TZD	tablets.	
	
Table	2.	Analysis	of	Sirdalud®	by	the	proposed	procedure.	
Labeled	amount	
(µg/mL)	
Proposed	procedure	
(µg/mL)	
RSD		
(%)	
R%		
(n=6)	
9.00 8.80	 2.12	 96.51‐100.11	
	
3.8.	Statistical	analysis	
	
Statistical	analysis	of	the	results	obtained	by	the	proposed	
method	and	 the	reference	method	for	TZD	was	carried	out	by	
“SPSS	statistical	package	version	11”.	The	significant	difference	
between	the	reference	method	and	the	described	method	was	
tested	by	one	way	ANOVA	(F‐test)	at	p	=	0.05	as	shown	in	Table	
1.	The	test	ascertained	that	there	was	no	significant	difference	
between	the	two	methods.	
	
4.	Conclusion	
	
The	proposed	method	 for	 the	determination	of	TZD	 is	 the	
first	spectrofluorometric	method	reported	for	the	drug	and	has	
the	 advantages	 of	 simplicity,	 precision,	 accuracy	 and	
convenience.	In	this	method,	TZD	analysis	has	been	developed	
based	on	the	quenching	of	the	fluorescence	of	thioglycolic	acid‐
capped	 CdS	 quantum	 dots.	 When	 the	 proposed	 method	 was	
applied	in	the	determination	of	TZD	in	tablets,	the	results	were	
in	 good	 agreement	 with	 the	 labeled	 amount	 showing	 no	
interference	 from	 excipients.	 The	 proposed	 method	 was	
validated	 showing	 satisfactory	 data	 for	 all	 method	 validation	
parameters	tested.	The	developed	method	can	be	conveniently	
used	by	quality	control	laboratories.	
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